Dendreon (DNDN) update #8—Intelligent debate on Provenge
Posted by intelledgement on Thu, 12 Apr 07
If you have been following the trials and tribulations of Dendreon, a speculative biotech play in our ISOP portfolio, then you might want to check a Provenge (Dendreon’s immuno therapy product for prostate cancer with the FDA are presently reviewing for possible approval) post on the Investor Village DNDN board by an intelligent and articulate bear. He cogently explains most of the serious concerns, both pre-approval and post-approval (which are the more salient issues at this point, in our opinion).
Be sure to peruse some of the replies, but at least those by croumagnon, fordwill1953, and most especially rancherho (this last being one of the best posts we have ever seen on any stock message board).